FDA touts new flexible approach to reviewing cell and gene therapies The US Food and Drug Administration (FDA) has announced it will take a flexible approach to reviewing all new cell and gene therapy (CGTs) biologics license applications (BLAs) to expedite the development of these products, rather than applying its flexibilities on a case-by-case basis. @

🚀 The biggest #JPMWeek2026 win you missed: The FDA is easing manufacturing rules (21 CFR 211) for Cell & Gene Therapy.

Lower costs. Faster trials. Massive win for biotech startups. 🧬

Read: www.raps.org/news-and-art...

#JPMWeek2026

Day 2:
1/ IPO Test: Eikon’s filing is the sector's litmus test. Will it open the floodgates?
2/ AI: $1B Lilly-Nvidia deal proves AI is the drug discovery backbone.
3/ FDA: Protocols eased for cell/gene therapy—faster & cheaper.

#o2hGroup #JPMWeek2026 #JPM #RESIJPM #LifeSciences #Biotech #Techbio #Innovation #Collaboration